JP2007523088A5 - - Google Patents

Download PDF

Info

Publication number
JP2007523088A5
JP2007523088A5 JP2006553341A JP2006553341A JP2007523088A5 JP 2007523088 A5 JP2007523088 A5 JP 2007523088A5 JP 2006553341 A JP2006553341 A JP 2006553341A JP 2006553341 A JP2006553341 A JP 2006553341A JP 2007523088 A5 JP2007523088 A5 JP 2007523088A5
Authority
JP
Japan
Prior art keywords
composition
antagonist
cells
viral
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006553341A
Other languages
English (en)
Japanese (ja)
Other versions
JP4903061B2 (ja
JP2007523088A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/004742 external-priority patent/WO2005079837A1/en
Publication of JP2007523088A publication Critical patent/JP2007523088A/ja
Publication of JP2007523088A5 publication Critical patent/JP2007523088A5/ja
Application granted granted Critical
Publication of JP4903061B2 publication Critical patent/JP4903061B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006553341A 2004-02-17 2005-02-15 Il−23活性を調節する方法;関連する試薬 Expired - Fee Related JP4903061B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54570804P 2004-02-17 2004-02-17
US60/545,708 2004-02-17
PCT/US2005/004742 WO2005079837A1 (en) 2004-02-17 2005-02-15 Methods of modulating il-23 activity; related reagents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011261668A Division JP2012092117A (ja) 2004-02-17 2011-11-30 Il−23活性を調節する方法;関連する試薬

Publications (3)

Publication Number Publication Date
JP2007523088A JP2007523088A (ja) 2007-08-16
JP2007523088A5 true JP2007523088A5 (cg-RX-API-DMAC7.html) 2008-02-28
JP4903061B2 JP4903061B2 (ja) 2012-03-21

Family

ID=34886185

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006553341A Expired - Fee Related JP4903061B2 (ja) 2004-02-17 2005-02-15 Il−23活性を調節する方法;関連する試薬
JP2011261668A Withdrawn JP2012092117A (ja) 2004-02-17 2011-11-30 Il−23活性を調節する方法;関連する試薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011261668A Withdrawn JP2012092117A (ja) 2004-02-17 2011-11-30 Il−23活性を調節する方法;関連する試薬

Country Status (12)

Country Link
US (1) US8263080B2 (cg-RX-API-DMAC7.html)
EP (1) EP1901768B1 (cg-RX-API-DMAC7.html)
JP (2) JP4903061B2 (cg-RX-API-DMAC7.html)
CN (1) CN1942201B (cg-RX-API-DMAC7.html)
AT (1) ATE533502T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005215527B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507794A (cg-RX-API-DMAC7.html)
CA (1) CA2556425A1 (cg-RX-API-DMAC7.html)
NO (1) NO20064194L (cg-RX-API-DMAC7.html)
NZ (1) NZ548897A (cg-RX-API-DMAC7.html)
WO (1) WO2005079837A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200606620B (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
NZ539271A (en) * 2002-10-30 2008-12-24 Genentech Inc Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23)
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
SI1937721T1 (sl) * 2005-08-25 2010-11-30 Lilly Co Eli Anti il protitelesa
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP2009540018A (ja) * 2006-06-13 2009-11-19 ザイモジェネティクス, インコーポレイテッド Il−17およびil−23アンタゴニストならびにその使用方法
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
CA2679381A1 (en) * 2007-02-28 2008-09-04 Schering Corporation Engineered anti-il-23r antibodies
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
BRPI0908312A2 (pt) 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
EP2427203B1 (en) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
EP2480251B1 (en) * 2009-09-21 2025-12-03 Peptinov Carrier conjugates of il-23-peptides and their induced antibodies
KR102049223B1 (ko) 2010-11-04 2019-11-28 베링거 인겔하임 인터내셔날 게엠베하 항-il-23 항체
CN109206516A (zh) 2012-05-03 2019-01-15 勃林格殷格翰国际有限公司 抗IL-23p19抗体
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN103837687A (zh) * 2014-03-10 2014-06-04 青岛康立泰药业有限公司 使用具有白细胞介素-12受体的细胞检测重组人白细胞介素-12体外活性的方法及应用
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
CA2959629C (en) 2014-09-03 2023-10-31 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
KR20170120616A (ko) 2015-02-04 2017-10-31 베링거 인겔하임 인터내셔날 게엠베하 염증성 질환의 치료 방법
KR101873499B1 (ko) * 2015-02-10 2018-07-03 주식회사 원메디칼 혈관 질환 진단용 바이오 마커 및 이의 용도
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
EP3634465A4 (en) * 2017-05-25 2021-01-20 The Broad Institute, Inc. LYMPHOCYTE ANTIGEN CD5 SIMILAR (CD5L) MONOMER, HOMODIMER AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHOD OF USE THEREOF
US20200147177A1 (en) * 2017-07-17 2020-05-14 Chu De Nantes - Centre Hospitalier Universitaire De Nantes Interleukin 12 (il12) or derivative thereof for use in the treatment of secondary disease
JP7516250B2 (ja) 2018-03-05 2024-07-16 ヤンセン バイオテツク,インコーポレーテツド 抗il-23特異的抗体を用いたクローン病の治療方法
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗lag3抗体および抗pd-1抗体の共-製剤
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
US6756481B2 (en) * 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
WO2003092610A2 (en) * 2002-05-01 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat hiv infection and aids
NZ539271A (en) * 2002-10-30 2008-12-24 Genentech Inc Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23)
AU2003303384A1 (en) * 2002-12-23 2004-07-22 Schering Corporation Uses of mammalian cytokine; related reagents
CA2511838C (en) * 2002-12-31 2014-05-06 Schering Corporation Uses of mammalian cytokine; related reagents
US20040219150A1 (en) * 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
ATE440864T1 (de) * 2003-03-10 2009-09-15 Schering Corp Verwendung von il-23-antagonisten; verwandte reagenzien
US7582297B2 (en) * 2003-04-11 2009-09-01 Medimmune, Llc Methods of treating respiratory conditions
EP1623011B1 (en) * 2003-05-09 2013-01-02 Janssen Biotech, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses

Similar Documents

Publication Publication Date Title
US20260049993A1 (en) Viral serology assays
Hamelin et al. Human metapneumovirus: a new player among respiratory viruses
US20230204568A1 (en) Measuring trail by lateral flow immunoassay
Lan et al. Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge
Rota et al. Comparison of the sensitivity of laboratory diagnostic methods from a well-characterized outbreak of mumps in New York city in 2009
Hamelin et al. Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease
Dakhama et al. Common respiratory viruses in lower airways of patients with acute hypersensitivity pneumonitis
US20220381780A1 (en) Viral strain serology assays
EP4033248B1 (en) System and method for analysis of mx1 and crp in blood
Oliva et al. Murine model for the study of influenza D virus
Huang et al. Profiles of acute cytokine and antibody responses in patients infected with avian influenza A H7N9
WO2023040026A1 (zh) 免疫层析检测试剂条和包含其的试剂盒及二者的应用
Vidaña et al. Heterogeneous pathological outcomes after experimental pH1N1 influenza infection in ferrets correlate with viral replication and host immune responses in the lung
JP2014518624A5 (cg-RX-API-DMAC7.html)
Welch et al. Detection of porcine parainfluenza virus type-1 antibody in swine serum using whole-virus ELISA, indirect fluorescence antibody and virus neutralizing assays
Schmidt et al. Effect of mucosal adjuvant IL-1β on heterotypic immunity in a pig influenza model
Wibawa et al. Comparison of serological assays for detecting antibodies in ducks exposed to H5 subtype avian influenza virus
Yang et al. Binding and entry of peste des petits ruminants virus into caprine endometrial epithelial cells profoundly affect early cellular gene expression
TW202128749A (zh) 辨識抗rs病毒之抗體、以及使用該抗體之免疫測定方法及免疫測定器具
Tut et al. Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection
JP2011509935A5 (cg-RX-API-DMAC7.html)
JP2021516340A5 (cg-RX-API-DMAC7.html)
JP2023546076A5 (cg-RX-API-DMAC7.html)
Watson et al. Isolation and characterisation of an H3N8 equine influenza virus in Australia, 2007
Isogawa et al. Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens